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Problem Identification
Opioid overdoses are a growing public health concern in Vermont.
 Between 2012 and 2017, the number of fatal opioid overdoses in Vermont nearly doubled, from

51 to 101.1

 Of all Vermont counties, Franklin County has the 3rd highest rate of fatal opioid overdoses. 1
 Nationally, up to 49% of adults personally know someone who has faced opioid addiction, and

10% know someone who has died because of it. 2

Naloxone can save lives… if people know how to use it.
 Only 20% of American adults know what naloxone is; that it can be given by a layperson; and that

it is available without a prescription. 3

 When informed about naloxone, up to 68% would be willing to use it to help someone who had

overdosed. 3

 For every overdose fatality in Vermont, 5 other people are saved by community-administered

naloxone. 4
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Public Health Cost
“[P]revious estimates of the economic cost of the opioid crisis greatly understate it by
undervaluing the most important component of the loss – fatalities resulting from
overdoses.”
Advisors5

-- White House Council of Economic

 In 2015, opioid overdoses killed 41,033 people in the United States. The White House Council of

Economic Advisors estimates the “cost” of these deaths at $431.7 billion. 5

 The cost of two units of Narcan (naloxone nasal spray) is approximately $150. 6
 A 2013 NIAID study found that naloxone distribution to heroin users was cost-effective, with an

incremental cost effectiveness ratio of $14,000 in the most conservative scenario. 7

 More recent data from Vermont indicate much greater cost effectiveness. In 2018, one Vermont social

service agency that distributes naloxone kits estimated a cost per life saved of $325-$450.8
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Community Perspective
Interview with Karen Heinlein-Grenier, Katie DeForge, and Maria Carlson, staff at Turning
Point Center of Franklin County:
 Turning Point has distributed free Narcan for 4 years, and has noted steadily increasing interest during

that time.

 Requests for Narcan come from a mixture of active users, people in treatment/recovery, and non-users.
 They do not always have follow-up with people who receive Narcan kits, so are not sure how often kits

are used.

 Recently they have seen more requests from elderly people, and more people referred by healthcare

providers.

 People may find it difficult to get Narcan from a pharmacy because:
 They are concerned about stigma from pharmacists and other customers, and lack of privacy at the

pharmacy counter.

 They worry that asking for Narcan will broadcast that they have opioids and make them a target.
 They do not know that it is available without a prescription, how much it will cost, or whether insurance

will cover it.
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Community Perspective, continued
Interview with Karen Heinlein-Grenier, Katie DeForge, and Maria Carlson, staff at
Turning Point Center of Franklin County:
 It is beneficial for people to carry Narcan even if they don’t know of anyone who abuses

opioids:

 If someone in their home has an opioid prescription, they may accidentally take an excess dose

because of memory decline or polypharmacy; or a child may gain access to the medication.

 A friend, family member, or coworker may be a “closet user.”
 Opioids may be cut into other drugs, such as marijuana or cocaine.
 People may encounter someone who has overdosed in a public setting – for example, slumped over

the steering wheel in a parking lot.

 Interviewees were enthusiastic about the idea of incorporating naloxone education into

routine primary care encounters, noting that this could provide the opportunity to educate
a “captive audience” and may have a positive normalizing effect.
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Intervention & Methodology
 During the course of routine primary care visits, patients who were not being

prescribed opioids or receiving treatment for opioid use disorder were asked:

“Many of our patients have friends and family who are affected by the opioid epidemic.
There is a medication called naloxone that you could use to save a life if someone around
you were to overdose. Would you like to learn more about naloxone while you’re
here today?”
 Patients who consented were instructed in how to use Narcan and given:
 A quick reference sheet summarizing when and how to use Narcan nasal spray, and what to

do afterward

 A list of local organizations that distribute free Narcan kits, and local pharmacies with prices

 The reference sheet was developed based on similar resources from the CDC,

Vermont Department of Health, and the Narcan package insert, and has a FleschKincaid grade level of 3.4 (i.e., a 3rd grade reading level).
6
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Results
 Over the course of 7 days in clinic, naloxone education was offered to all patients who

were not receiving opioid prescriptions – a total of 7 patients; 2 said yes (28%).

 After naloxone education:
 100% said that they plan to obtain naloxone.
 100% said that they would not be surprised if they witnessed an overdose in the next 12

months.

 100% said that they would feel confident about administering naloxone if necessary.

 Patient feedback:
 “Honestly, you really never know when you might need this” – recently passed a driver

who was pulled over unconscious with a child in the car, and called 911, but would have used
naloxone if she’d had it

 Had heard of Narcan but “I had no idea that anyone can get it, or that it’s so simple to use – this

is definitely life-changing information”
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Evaluation & Limitations
Although naloxone education was well-received by those patients who received it, the number of patients
participating in this project was very small, for three reasons:
1. The duration of the project was very short.
2. The vast majority of patients encountered were not part of the target group for this
project, because they were receiving opioids (either as a component of medication-assisted treatment or
for chronic pain).
3. Almost three-quarters of eligible patients declined naloxone education, largely because they
did not perceive it as personally relevant.
 Most declined because to their knowledge, none of their friends or family members used opioids.
 One patient has a household member who is prescribed opioids, but did not perceive him to be at risk

of overdose.

 One patient stated that he did not believe that people who overdose should be revived.
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Future Recommendations
Potential directions for future work in this area include:
 Conducting a longer trial of this project, possibly in a different population in which

fewer patients are being prescribed opioids.

 Develop materials that convey to patients that even if they do not know of friends or

family who abuse opioids, they may still be in a position to save someone’s life.

 Determine demographic characteristics of patients who are more likely to consent to

naloxone education, and develop recommendations regarding who should be offered
naloxone education, when, and how often.

 Initiate collaboration with the Vermont Department of Health or other community

agencies in order to distribute free Narcan kits from the office.

 Hold focus groups with community members to identify other needs and strategies

for supporting family and friends of opioid users in a primary care setting.
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Interview Consent

Thank you for agreeing to be interviewed. This project is a requirement for the
Family Medicine clerkship. It will be stored on the Dana Library ScholarWorks
website. Your name will be attached to your interview and you may be cited directly
or indirectly in subsequent unpublished or published work. The interviewer affirms
that he/she has explained the nature and purpose of this project. The interviewee
affirms that he/she has consented to this interview. Yes _X__ / No _____
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